4月28日，佰仁医疗获西南证券买入评级，近一个月佰仁医疗获得2份研报关注。
研报预计2024-2026年归母净利润1.5、2、2.6亿元。研报认为，作为以动物源性植（介）入材料为平台的创新龙头，未来潜力较大。
风险提示：研发失败风险、汇率波动风险、市场开拓风险、贸易摩擦风险。
佰仁医疗获西南证券买入评级，限位可扩外科瓣放量在即，高研发助力产品梯队布局
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.